TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.
Related news for (TCON)
- TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
- TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
- TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
- TRACON Pharmaceuticals Announces Reverse Stock Split